Biolatam attracts biotechnology risk capital funds managing a total of over 3 billion euros
(Thomson Reuters ONE) -
* Proexport Colombia will support the presence of international investment
funds
* 14 firms have so far confirmed their attendance, the organisation expects to
bring together 25 companies in Bogotá
Madrid, 14 November 2013. The first edition of Biolatam, the biggest event for
global biotechnology with a focus on Latin America, which will take place in
Bogota (Colombia) on the 9th and 10th of December of this year, will be a key
meeting point for investors and entrepreneurs from across the life sciences.
For this event, Proexport Colombia, the Colombian government agency responsible
for the promotion of direct foreign investement into the country, has
facilitiated the attendance of international investement funds managing a total
of over 3 billion euros in portfolios centred around health and technology. So
far 14 investement funds have confirmed their attendance but the final number is
expected to rise to 25.
The investment funds whose attendance has been confirmed are Austral Capital
(Chile), Burrill Brasil Gestão de Recursos (Brazil), CRB INVERBIO S.A. SGECR
(Spain), Inveready Biotech II SCR (Spain), Ventac Partners (US), Ysios Capital
Partners SGECR (Spain), ZFunction (US), Wellington Partners (UK), Forbion
Capital Partners (Netherlands), Flagship Ventures (US), Edrip (Edmond de
Rothschild Investment Partners), from France, Inversiones de Vanguardia
(Colombia), Velum Partners (Colombia) and the Red Nacional de Ángeles
Inversionistas (Colombia) led by Fundación Bavaria.
Amongst the most important are Wellington, based in London, which manages four
funds comprising over 800 millon euros invested in 30 companies working in areas
such as medical technology, diagnosis, therapy and industrial biotechnology;
Flagship, from Boston, which manages 900 million euros for seed and early-stage
investments, with some later stage value investments. Its portfolio is made up
of 28 companies. Forbion, based in Amsterdam, manages four funds accounting for
over 450 million euros, has invested in companies working on late stage
preclinical / early stage clinical development programs. It has 27 companies in
its portfolio.
The Biolatam conference programme will include a especial Seminar, on the 9th of
December, which will be made up of three sessions focused on financing. The
first will be, Public Policy to support risk capital in biotechnology, the
second, What are investors searching for in Latin American Biotechnology and the
third seminar will be on Risk Capital specialised in Biotechnology; what
international investors experience. During the seminar, which will be presided
by the former Spanish minister for Science and Innovation, Cristina Garmendia,
successful case studies of PPP funds will be studied and cross-shareholdings
between Europe, the US and Latin America will be debated. The challenge of how
to attract big fortunes and business angels to the sector will also be covered.
During the first session speakers will include Consuelo Valverde, founder of
ZFunction (US); Felipe Camposano, General Partner de Austral Capital and
Presidente of the Chilean Association for Biotechnology (Chile) (ASEMBIO) and
representatives of iNNpulsa (Colombia) and the CDTI (Spain). During the second
session, which will be moderated by Ángel Santos, Director of Business
Development at CRB Inverbío SGECR (Spain), the speakers will include João Paulo
Poiares Baptista, Director General of Burrill Brasil Gestão de Recursos S.A.
(Brazil) and Santiago de Torres, President of Inveready Biotech II SCR (Spain).
The last session will be moderated by Joël Jean-Mairet, Managing Partner of
Ysios Capital Partners (Spain) and the confirmed speakers are Gilles Nobercourt,
Partner of Edmond de Rothschild (France); Sander Slootweg, Managing Partner of
Forbion Capital Partners (Netherlands); Ignacio Martinez, Partner of Flagship
Ventures (US-MA) and Arun R. Jayadev, Principal of Wellington Partners (UK).
About BIOLATAM
BIOLATAM is a global partnering forum with a Latin American focus, it is open to
companies, researchers and risk capital entities. The partnering section will be
managed using PartneringOne software provided by EBD Group - which has been a
service prider for Biospain and other high profile fairs- and will include a
conference programme on bioeconomy, biocomfuels, advanced therapies, food
biotechnology, personalised medicine, health products and risk capital as well
as other subject areas.
For this first edition of BIOLATAM, we expect to exceed 500 attendees, with a
high participation of US delegates, Latin American and European countries, as
well as the presence of relevant biotechnology markets, such as that of Japan,
Israel and Canada.
The event aspires to take place on a biennal basis on odd numbered years with
the objective of becoming the leading forum in Latin America for the
biotechnology sector and the promotion and development of business relationships
between biotechnology companies as well as their relationship with user and
associated sectors (pharma, health products, food, veterinary products, energy,
among others) from all over the world but with particular interests in Latin
American countries.
http://www.biolatam.org/es/index.html
About ASEBIO
The Spanish Bioindustry Association (ASEBIO) comprises 255 members, mainly small
businesses born out of the research activities of universities and national
research centres.
ASEBIO has, since 1999, been a meeting point and platform for the promotion of
those organisations interested in the national biotechnology field. To that end,
ASEBIO works closely with regional, national and European administrations, as
well as all those social organisations interested in the use of biotechnology
for the improvement of our quality of life, the environment and the creation of
highly skilled jobs.
About Invest in Bogota
Invest in Bogota is the investment promotion agency for the Bogota region, a
public-private partnership between the Bogota Chamber of Commerce and Bogota
City Council. Its mission is to support investors who are exploring
opportunities in Bogota. In 2009 The World Bank ranked it as the best non-OECD
investment promotion agency in the world. It offers specialised services to
investors, on a free of charge and fully confidential basis, at every stage of
the investment process: the exploratory phase, the decision making stage, the
start-up process, the operational phase and in reinvestement.
About Proexport
Proexport is the entity that promotes international tourism, foreign investment
and non-traditional exports in Colombia. Through its national and international
network of offices, it offers support and integral consultancy to clients
through services or instruments aimed at facilitating design and execution of
its globalization strategy, which seeks to generate, develop and close business
opportunities.
For further information please contact:
Lucía Cecilia
Head of Communications at BIOLATAM and ASEBIO
Telephone. + 34 91 2109374/10
Fax. +34 91 2500063
Mobile: +34 663 117 293
e-mail: lcecilia(at)asebio.com
comunicacion(at)biolatam.org
Adriana Rodríguez C.
Marketing and Communications Officer at Invest in Bogota
Telephone. +57 1 1 7423030
e-mail: arodriguez(at)investinbogota.org
Press release (PDF):
http://hugin.info/159105/R/1743388/586441.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Asociación Española de Bioempresas via Thomson Reuters ONE
[HUG#1743388]
Datum: 14.11.2013 - 18:03 Uhr
Sprache: Deutsch
News-ID 316824
Anzahl Zeichen: 8770
contact information:
Town:
MADRID
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biolatam attracts biotechnology risk capital funds managing a total of over 3 billion euros"
steht unter der journalistisch-redaktionellen Verantwortung von
Asociación Española de Bioempresas (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
